EASTONBIOPHARMACEUTICALS(SH:688513) Zheng Quan Zhi Xing·2025-09-05 09:16Group 1 - The company has received the drug registration certificate for Pirfenidone Tablets from the National Medical Products Administration, indicating compliance with drug registration requirements [1][2] - The drug is classified as a Class 4 chemical drug and is indicated for the treatment of partial seizures in adults and children aged 4 years and above [2] - The original developer of the drug is Eisai Europe Limited, which first launched it in the EU in July 2012, followed by approvals in the US and Japan [2] Group 2 - The sales amount for the original drug in 2024 is projected to be approximately 96.52 million yuan, reflecting a year-on-year growth of 39.74% [2] - The company has entered into a commercial cooperation agreement with Anhui Wanbang Pharmaceutical Technology Co., Ltd., where Wanbang will handle sales and promotion of the drug [2] - The company is responsible for the production and supply of the drug and will share in the profits from sales after the drug is launched [2]